405 related articles for article (PubMed ID: 25587128)
21. Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans.
Takeuchi K; Sugiura T; Matsubara K; Sato R; Shimizu T; Masuo Y; Horikawa M; Nakamichi N; Ishiwata N; Kato Y
Drug Metab Dispos; 2014 Apr; 42(4):726-34. PubMed ID: 24440960
[TBL] [Abstract][Full Text] [Related]
22. Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.
Generaux GT; Bonomo FM; Johnson M; Doan KM
Xenobiotica; 2011 Aug; 41(8):639-51. PubMed ID: 21425956
[TBL] [Abstract][Full Text] [Related]
23. Role of the breast cancer resistance protein (ABCG2) in drug transport.
Mao Q; Unadkat JD
AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
[TBL] [Abstract][Full Text] [Related]
24. Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors.
Oostendorp RL; van de Steeg E; van der Kruijssen CM; Beijnen JH; Kenworthy KE; Schinkel AH; Schellens JH
Drug Metab Dispos; 2009 Apr; 37(4):917-23. PubMed ID: 19139163
[TBL] [Abstract][Full Text] [Related]
25. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans.
Yamasaki Y; Ieiri I; Kusuhara H; Sasaki T; Kimura M; Tabuchi H; Ando Y; Irie S; Ware J; Nakai Y; Higuchi S; Sugiyama Y
Clin Pharmacol Ther; 2008 Jul; 84(1):95-103. PubMed ID: 18167504
[TBL] [Abstract][Full Text] [Related]
26. Obatoclax as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell lines.
Theile D; Allendorf D; Köhler BC; Jassowicz A; Weiss J
J Pharm Pharmacol; 2015 Nov; 67(11):1575-84. PubMed ID: 26255619
[TBL] [Abstract][Full Text] [Related]
27. Pharmacogenomic importance of ABCG2.
Cusatis G; Sparreboom A
Pharmacogenomics; 2008 Aug; 9(8):1005-9. PubMed ID: 18681776
[TBL] [Abstract][Full Text] [Related]
28. Novel inhibitors of breast cancer resistance protein (BCRP, ABCG2) among marketed drugs.
Deng F; Sjöstedt N; Santo M; Neuvonen M; Niemi M; Kidron H
Eur J Pharm Sci; 2023 Feb; 181():106362. PubMed ID: 36529162
[TBL] [Abstract][Full Text] [Related]
29. Calibrating the In Vitro-In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK Models.
Sane R; Cheung KWK; Kovács P; Farasyn T; Li R; Bui A; Musib L; Kis E; Plise E; Gáborik Z
Drug Metab Dispos; 2020 Dec; 48(12):1264-1270. PubMed ID: 33037044
[TBL] [Abstract][Full Text] [Related]
30. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Dahan A; Amidon GL
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
[TBL] [Abstract][Full Text] [Related]
31. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.
Imai Y; Tsukahara S; Asada S; Sugimoto Y
Cancer Res; 2004 Jun; 64(12):4346-52. PubMed ID: 15205350
[TBL] [Abstract][Full Text] [Related]
32. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.
Zhou XF; Yang X; Wang Q; Coburn RA; Morris ME
Drug Metab Dispos; 2005 Aug; 33(8):1220-8. PubMed ID: 15908473
[TBL] [Abstract][Full Text] [Related]
33. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Doyle L; Ross DD
Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
[TBL] [Abstract][Full Text] [Related]
34. Deletion of Abcg2 has differential effects on excretion and pharmacokinetics of probe substrates in rats.
Huang L; Be X; Tchaparian EH; Colletti AE; Roberts J; Langley M; Ling Y; Wong BK; Jin L
J Pharmacol Exp Ther; 2012 Nov; 343(2):316-24. PubMed ID: 22869929
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe.
Urquhart BL; Ware JA; Tirona RG; Ho RH; Leake BF; Schwarz UI; Zaher H; Palandra J; Gregor JC; Dresser GK; Kim RB
Pharmacogenet Genomics; 2008 May; 18(5):439-48. PubMed ID: 18408567
[TBL] [Abstract][Full Text] [Related]
36. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
[TBL] [Abstract][Full Text] [Related]
37. Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype.
Prasad B; Lai Y; Lin Y; Unadkat JD
J Pharm Sci; 2013 Mar; 102(3):787-93. PubMed ID: 23280364
[TBL] [Abstract][Full Text] [Related]
38. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
Zhang S; Wang X; Sagawa K; Morris ME
Drug Metab Dispos; 2005 Mar; 33(3):341-8. PubMed ID: 15608138
[TBL] [Abstract][Full Text] [Related]
39. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
Graber-Maier A; Gutmann H; Drewe J
Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
[TBL] [Abstract][Full Text] [Related]
40. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).
Gupta A; Zhang Y; Unadkat JD; Mao Q
J Pharmacol Exp Ther; 2004 Jul; 310(1):334-41. PubMed ID: 15007102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
